LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer

Zhang Hongkai; Zhang Jianni; Dong Lining; Ma Rong

doi:10.1515/med-2021-0012

Open Medicine (Dec 2020)

LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer

Zhang Hongkai,
Zhang Jianni,
Dong Lining,
Ma Rong

Affiliations

Zhang Hongkai: Department of Cell Medicine, International Healthy Cells Rehabilitation Association, Shanghai Liangliang Biotechnology Co., Ltd, No. 876 Taogan Road, Sheshan District 201602, Shanghai, China
Zhang Jianni: Department of Cell Medicine, International Healthy Cells Rehabilitation Association, Shanghai Liangliang Biotechnology Co., Ltd, No. 876 Taogan Road, Sheshan District 201602, Shanghai, China
Dong Lining: Department of Cell Medicine, International Healthy Cells Rehabilitation Association, Shanghai Liangliang Biotechnology Co., Ltd, No. 876 Taogan Road, Sheshan District 201602, Shanghai, China
Ma Rong: Department of Cell Medicine, International Healthy Cells Rehabilitation Association, Shanghai Liangliang Biotechnology Co., Ltd, No. 876 Taogan Road, Sheshan District 201602, Shanghai, China

DOI: https://doi.org/10.1515/med-2021-0012
Journal volume & issue: Vol. 16, no. 1
pp. 68 – 80

Abstract

Read online

Tamoxifen (TAMR) resistance remains a massive obstacle for breast cancer (BC) management. The precise parts of long non-coding RNA ataxin 8 opposite strand (ATXN8OS) in BC TAMR resistance have not been defined.

Published in Open Medicine

ISSN: 2391-5463 (Online)
Publisher: De Gruyter
Country of publisher: Poland
LCC subjects: Medicine
Website: https://www.degruyter.com/journal/key/med/html

About the journal

Abstract

Keywords